<DOC>
	<DOCNO>NCT01911897</DOCNO>
	<brief_summary>To evaluate safety performance MobiusHD system subject resistant hypertension .</brief_summary>
	<brief_title>Controlling Lowering Blood Pressure With The MOBIUSHD™ ( CALM-FIM_EUR )</brief_title>
	<detailed_description>This open-label , multicenter , first-in-man clinical trial conduct Europe . Eligible subject stage 2 resistant systemic arterial hypertension currently treate4d minimum three ( 3 ) anti-hypertensive drug , consent study participation assign treatment MobiusHD system . Potential study participant consent screen two ( 2 ) baseline visit begin least 30 day prior MobiusHD placement . Qualified patient undergo placement MobiusHD angiographic visualization , follow 36 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office cuff SBP ≥ 160 mmHg measure per protocol instruction ( Appendix IV ) follow least one ( 1 ) month maximally tolerate therapy least three ( 3 ) antihypertensive medication , least one ( 1 ) must diuretic unless patient history intolerance , ineffectiveness contraindication . Any combination medication count per active ingredient ( example , Zestoretic ( Lisinopril +HCTZ ) equal two ( 2 ) antihypertensive medication ) Known clinically suspect baroreflex failure autonomic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension</keyword>
</DOC>